Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Active, not recruiting · NCT02436707 · Registry updated 2026-09-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-09-17 | NCT02436707 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Canadian Cancer Trials Group | 73 |
| Janssen, LP | 23 |
| Karyopharm Therapeutics Inc | 25 |
| Roche Pharma AG | 59 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Allan Blair Cancer Centre | Regina | Canada | 76 |
| Arthur J.E. Child Comprehensive Cancer Centre | Calgary | Canada | 45 |
| BCCA - Vancouver | Vancouver | Canada | 22 |
| CancerCare Manitoba | Winnipeg | Canada | 98 |
| CHU de Quebec-Hopital l'Enfant-Jesus (HEJ) | Québec | Canada | 5 |
| CHUM-Centre Hospitalier de l'Universite de Montreal | Montreal | Canada | 20 |
| Cross Cancer Institute | Edmonton | Canada | 146 |
| Kingston Health Sciences Centre | Kingston | Canada | 91 |
| Ottawa Hospital Research Institute | Ottawa | Canada | 46 |
| QEII Health Sciences Centre | Halifax | Canada | 11 |
| University Health Network | Toronto | Canada | 52 |